Fig. 2.

a IEQ Total score change at double-blind endpoint from open-label baseline, by relapse status. An ANOVA model was fitted with IEQ total score change at DB endpoint from OL baseline as outcome variable, and study ID and relapse status as factors. b IEQ Total score change at double-blind endpoint from open-label baseline, for patients who were on oral antipsychotics prior to study entry. A mixed model was fitted with IEQ total score as the outcome variable, and study ID and time points (OL baseline, DB endpoint) as factors. N = 663